🔴 Beam Therapeutics is trading 4.1% down today amid broader biotech sector weakness

Beam Therapeutics is trading 4.1% down at $25.40 amid a sharp pullback in biotechnology stocks.

• The move appears tied to broader sector weakness, as the biotech ETF (XBI) is down over 3% despite major indices trading slightly higher.
• Recent gains following FDA clearance for BEAM-304 are facing pressure from risk-off sentiment in high-growth biotech names.
• No fresh company-specific news or earnings were reported today to account for the decline.